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BACKGROUND: Genetic hallmark of atypical teratoid/rhabdoid tumor 
(AT/RT) is loss-of-function variants or deletions in SMARCB1 gene on 
22q11.2 chromosome, which is common to extracranial malignant rhabdoid 
tumors (MRT). Previous studies demonstrated that approximately one-thirds 
of AT/RT and extracranial MRT patients harbored germline SMARCB1 
variants as the rhabdoid tumor predisposing syndrome. We studied herein 
intensive analysis of the SMARCB1 gene in AT/RT and extracranial MRT 
patients focusing on prevalence of germline genetic variants. PROCEDURE: 
In total, 16 patients were included. Both tumor-derived DNA and germline 
DNA were obtained from all patients. First, screening for SMARCB1 alter-
ations in the tumor specimens was done by direct sequencing, ddPCR and 
SNP array analysis. Then, analysis of germline DNA samples focusing on 
the genomic abnormalities detected in the paired tumors in each case was 
performed. RESULTS: In eight of 16 cases (50%), genomic alterations ob-
served in the tumor-derived DNA were also detected in the germline DNA. 
It is worth noting that three patients had germline mosaicism. Two of three 
patients had mosaic deletion, including SMARCB1 region, and the average 
copy number of the deleted region in the SMARCB1 gene in the germline 
was 1.60 and 1.76. For another patient, the fraction of SMARCB1 vari-
ants in normal cells was as low as 1.7%. CONCLUSIONS: Approximately 
half the MRT cases in this study had SMARCB1 germline alterations. Con-
sidering the presence of low-frequency mosaicisms which conventional 
methods might overlook, inherited germline variants in predisposition genes 
are more important than previously assumed for the pathogenesis of pedi-
atric cancers.
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Rhabdoid tumors (RT) are rare but highly aggressive pediatric neoplasms. 
These tumors carry homozygous loss-of-function alterations of SMARCB1 
in almost all cases with an otherwise low mutational load. RT arise at dif-
ferent intracranial (ATRT) as well as extracranial (MRT) anatomical sites. 
Three main molecular subgroups (ATRT-SHH, ATRT-TYR, ATRT-MYC) 
have been characterized for ATRT which are epigenetically and clinically 
diverse, while MRT show remarkable similarities with ATRT-MYC distinct 
from ATRT-SHH and ATRT-TYR. Even though there are hypotheses about 
various cells of origin among RT subgroups, precursor cells of RT have not 
yet been identified. Previous studies on the temporal control of SMARCB1 
knockout in genetically engineered mouse models have unveiled a tight vul-
nerable time frame during embryogenesis with regard to the susceptibility of 
precursor cells to result in RT. In this study, we employed single-cell RNA 
sequencing to describe the intra- and intertumoral heterogeneity of murine 
ATRT-SHH and -MYC as well as extracranial MYC tumor cells. We de-
fined subgroup-specific tumor markers for all RT classes but also observed 
a notable overlap of gene expression patterns in all MYC subgroups. By 
comparing these single-cell transcriptomes with available single-cell maps of 
early embryogenesis, we gained first insights into the cellular origin of RT. 
Finally, unsupervised clustering of published human RT methylation data 
and healthy control tissues confirmed the existence of different cells of origin 
for intracranial SHH tumors and MYC tumors independent of their anatom-
ical localizations.
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Atypical teratoid/rhabdoid tumors (ATRT) are pediatric brain neoplasms 
that are known for their heterogeneity concerning pathophysiology and 
outcome. The three genetically rather uniform but epigenetically distinct 
molecular subgroups of ATRT alone do not sufficiently explain the clinical 
heterogeneity. Therefore, we examined the tumor microenvironment (TME) 
in the context of tumor diversity. By using multiplex-immunofluorescent 
staining and single-cell RNA sequencing (scRNA-seq) we unveiled the pan-
macrophage marker CD68 as a subgroup-independent negative prognostic 
marker for survival of ATRT patients. ScRNA-seq analysis of murine ATRT-
SHH, ATRT-MYC and extracranial RT (eRT) provide a delineation of the 
TME, which is predominantly infiltrated by myeloid cells: more specifically a 
microglia-enriched niche in ATRT-SHH and a bone marrow-derived macro-
phage infiltration in ATRT-MYC and eRT. Exploring the cell-cell commu-
nication of tumor cells with tumor-associated immune cells, we found that 
Cd68+ tumor-associated macrophages (TAMs) are central to intercellular 
communication with tumor cells. Moreover, we uncovered distinct tumor 
phenotypes in murine ATRT-MYC that share genetic traits with TAMs. 
These intermediary cells considerably increase the intratumoral heterogen-
eity of ATRT-MYC tumors. In vitro co-culture experiments recapitulated 
the capability of ATRT-MYC cells to interchange cell material with macro-
phages extensively, in contrast to ATRT-SHH cells. We found that microglia 
are less involved in the exchange of information with ATRT cells and that 
direct contact is a prerequisite for incorporation. A relapse xenograft model 
implied that intermediary cells are involved in the acquisition of chemo-
therapy resistance. We show evidence that TAM-tumor cell interaction is one 
mechanism of chemotherapy resistance and relapse in ATRT.
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Atypical Teratoid Rhabdoid Tumors (ATRT) are aggressive brain ma-
lignancies of the infant. Despite intensive multimodal therapy, the overall 
prognosis remains poor, making investigations on targeted therapies crucial. 
Arsenic trioxide (ATO) is known to inhibit cell growth of ATRT in vitro 
and in vivo but its efficacy in solid tumors is limited by its adverse effects. 
We aimed to characterize whether a nanoparticle-based drug delivery could 
overcome these limitations. Therefore metal-organic frameworks containing 
ATO (MOF-ATO) were constructed. To improve drug specificity further, 
we searched for unique proteins on the surface of ATRT, in order to create 
antibody-drug-conjugates out of MOF-ATO and an ATRT-specific ligand. 
ATRT are marked by a biallelic loss of SMARCB1, which results in an ac-
tivation of the repressive histone methyltransferase EZH2. After chemical 
inhibition of EZH2 with GSK126, a mass spectrometric based screening 
for differentially expressed surface proteins was performed. Treatment with 
ATO, as well as MOF-ATO and GSK126 each reduces the cell viability of 
ATRT cell lines. It results in a cell cycle arrest and an induction in apop-
tosis, being analysed via MTT test and flow cytometry. GSK126 treatment 
causes a significant upregulation of several cell surface proteins, upon them 
the Lymphocyte antigen 6 family member D (LY6D). Being rarely expressed 
on other human cells, this protein is an interesting candidate. An antibody-
drug-conjugate consisting of MOF-ATO and LY6D-ligands could be a 
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